(Q51711166)

10 April 2018

title

The Comprehensive in Vitro Proarrhythmia Assay (CiPA) initiative - Update on progress. (English)

1 reference

10 April 2018

1 reference

Thomas Colatsky

1

1 reference

10 April 2018

Bernard Fermini

2

1 reference

10 April 2018

Gary Gintant

3

1 reference

10 April 2018

Jennifer B Pierson

4

1 reference

10 April 2018

Philip Sager

5

1 reference

10 April 2018

Yuko Sekino

6

1 reference

10 April 2018

David G Strauss

7

1 reference

10 April 2018

Norman Stockbridge

8

1 reference

10 April 2018

publication date

6 June 2016

1 reference

10 April 2018

Journal of Pharmacological and Toxicological Methods

published in

1 reference

10 April 2018

volume

81

1 reference

10 April 2018

page(s)

15-20

1 reference

10 April 2018

Improvement of acquisition and analysis methods in multi-electrode array experiments with iPS cell-derived cardiomyocytes

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Inhibition of the late sodium current as a potential cardioprotective principle: effects of the late sodium current inhibitor ranolazine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

High-throughput multi-parameter profiling of electrophysiological drug effects in human embryonic stem cell derived cardiomyocytes using multi-electrode arrays.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

An evaluation of 30 clinical drugs against the comprehensive in vitro proarrhythmia assay (CiPA) proposed ion channel panel

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

High-throughput screening of drug-binding dynamics to HERG improves early drug safety assessment.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

hERG inhibitors with similar potency but different binding kinetics do not pose the same proarrhythmic risk: implications for drug safety assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

High-throughput cardiac safety evaluation and multi-parameter arrhythmia profiling of cardiomyocytes using microelectrode arrays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Evolution of strategies to improve preclinical cardiac safety testing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Comparison of electrophysiological data from human-induced pluripotent stem cell-derived cardiomyocytes to functional preclinical safety assays

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Image-based evaluation of contraction-relaxation kinetics of human-induced pluripotent stem cell-derived cardiomyocytes: Correlation and complementarity with extracellular electrophysiology.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Differentiating drug-induced multichannel block on the electrocardiogram: randomized study of dofetilide, quinidine, ranolazine, and verapamil.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Variability in the measurement of hERG potassium channel inhibition: effects of temperature and stimulus pattern

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

CSAHi study: Evaluation of multi-electrode array in combination with human iPS cell-derived cardiomyocytes to predict drug-induced QT prolongation and arrhythmia--effects of 7 reference compounds at 10 facilities.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Combined pharmacological block of I(Kr) and I(Ks) increases short-term QT interval variability and provokes torsades de pointes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

The electrophysiological development of cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

High Throughput Measurement of Ca++ Dynamics in Human Stem Cell-Derived Cardiomyocytes by Kinetic Image Cytometery: A Cardiac Risk Assessment Characterization Using a Large Panel of Cardioactive and Inactive Compounds

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Investigating dynamic protocol-dependence of hERG potassium channel inhibition at 37 degrees C: Cisapride versus dofetilide

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Sodium overload due to a persistent current that attenuates the arrhythmogenic potential of a novel LQT3 mutation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Assessment of testing methods for drug-induced repolarization delay and arrhythmias in an iPS cell-derived cardiomyocyte sheet: multi-site validation study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Availability of human induced pluripotent stem cell-derived cardiomyocytes in assessment of drug potential for QT prolongation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Quantitative comparison of cardiac ventricular myocyte electrophysiology and response to drugs in human and nonhuman species.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Early Drug Discovery Prediction of Proarrhythmia Potential and Its Covariates

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

A history of the role of the hERG channel in cardiac risk assessment

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Rechanneling the cardiac proarrhythmia safety paradigm: a meeting report from the Cardiac Safety Research Consortium.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Accumulation of slowly activating delayed rectifier potassium current (IKs) in canine ventricular myocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Low-density plating is sufficient to induce cardiac hypertrophy and electrical remodeling in highly purified human iPS cell-derived cardiomyocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Lessons from the heart: mirroring electrophysiological characteristics during cardiac development to in vitro differentiation of stem cell derived cardiomyocytes.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Cardiac ventricular repolarization reserve: a principle for understanding drug-related proarrhythmic risk.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Self-augmentation of the lengthening of repolarization is related to the shape of the cardiac action potential: implications for reverse rate dependency

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Transient outward K+ current reduction prolongs action potentials and promotes afterdepolarisations: a dynamic-clamp study in human and rabbit cardiac atrial myocytes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Estimation of potency of HERG channel blockers: impact of voltage protocol and temperature

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

Possible effects of inhibition of IKr and IKs on field-potential waveforms in the human iPS cell-derived cardiomyocytes sheet.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.VASCN.2016.06.002

10.1016/J.VASCN.2016.06.002

7 January 2021

Identifiers

DOI

1 reference

10 April 2018

PubMed ID

27282641

1 reference

10 April 2018